<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OXYCODONE HYDROCHLORIDE AND ASPIRIN- oxycodone hydrochloride and aspirin tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1>OXYCODONE AND ASPIRIN TABLETS, USP <br> CII<br>4.8355 mg/325 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each oxycodone and aspirin tablet contains:</p>
<p>Oxycodone Hydrochloride, USP 4.8355 mg<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p>Aspirin, USP 325 mg</p>
<p>Oxycodone and aspirin tablets also contain the following inactive ingredients: corn starch, colloidal silicon dioxide, microcrystalline cellulose, and stearic acid.</p>
<p>The oxycodone hydrochloride component is Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, hydrochloride, (5a)-., a white to off-white, hygroscopic crystals or powder, odorless, soluble in water; slightly soluble in alcohol and is represented by the following structural formula: </p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b82495ce-8d77-4e12-a064-274a88448ba3&amp;name=oxycodone-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">18</span>N<span class="Sub">21</span>NO<span class="Sub">4</span> • HCl      MW 351.82</p>
</div>
<p>The aspirin component is 2-(acetyloxy)-, Benzoic acid, a white crystal, commonly tabular or needle-like, or white, crystalline powder. Is odorless or has a <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> odor. Is stable in dry air; in moist air it gradually hydrolyzes to salicylic and acetic acids. Slightly soluble in water; freely soluble in alcohol; soluble in chloroform and in ether; sparingly soluble in absolute ether and is represented by the following structural formula:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b82495ce-8d77-4e12-a064-274a88448ba3&amp;name=oxycodone-02.jpg"><p class="MultiMediaCaption">C<span class="Sub">9</span>H<span class="Sub">8</span>O<span class="Sub">4</span>      MW 180.16</p>
</div>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>4.8355 mg oxycodone HCl is equivalent to 4.3346 mg of oxycodone as the free base.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First">Oxycodone is a semisynthetic pure opioid agonist whose principal therapeutic action is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Other pharmacological effects of oxycodone include anxiolysis, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> and feelings of relaxation. These effects are mediated by receptors (notably µ and κ) in the central nervous system for endogenous opioid-like compounds such as endorphins and enkephalins. Oxycodone produces <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> through direct activity at respiratory centers in the brain stem and depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the center of the medulla.</p>
<p>Aspirin (acetylsalicylic acid) works by inhibiting the body's production of prostaglandins, including prostaglandins involved in <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Prostaglandins cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> sensations by stimulating muscle contractions and dilating blood vessels throughout the body. In the CNS, aspirin works on the hypothalamus heat-regulating center to reduce <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, however, other mechanisms may be involved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Gastrointestinal Tract and Other Smooth Muscle</h2>
<p class="First">Oxycodone reduces motility by increasing smooth muscle tone in the stomach and duodenum. In the small intestine, digestion of food is delayed by decreases in propulsive contractions. Other opioid effects include contraction of biliary tract smooth muscle, spasm of the Sphincter of Oddi, increased ureteral and bladder sphincter tone, and a reduction in uterine tone.</p>
<p>Aspirin can produce <span class="product-label-link" type="condition" conceptid="4168618" conceptname="Injury of gastrointestinal tract">gastrointestinal injury</span> (lesions, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>) through a mechanism that is not yet completely understood, but may involve a reduction in eicosanoid synthesis by the gastric mucosa. Decreased production of prostaglandins may compromise the defenses of the gastric mucosa and the activity of substances involved in tissue repair and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> healing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Cardiovascular System</h2>
<p class="First">Oxycodone may produce a release of histamine and may be associated with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and other symptoms, such as <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Platelet Aggregation</h2>
<p class="First">Aspirin affects platelet aggregation by irreversibly inhibiting prostaglandin cyclo-oxygenase. This effect lasts for the life of the platelet and prevents the formation of the platelet aggregating factor thromboxane A2. Nonacetylated salicylates do not inhibit this enzyme and have no effect on platelet aggregation. At somewhat higher doses, aspirin reversibly inhibits the formation of prostaglandin 12 (prostacyclin), which is an arterial vasodilator and inhibits platelet aggregation.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.5"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">The mean absolute oral bioavailability of oxycodone in cancer patients was reported to be about 87%. This high oral bioavailability is due to low pre-systemic elimination and/or first-pass metabolism. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The volume of distribution after intravenous administration is 211.9 ±186.6 L. Oxycodone has been shown to be 45% bound to human plasma proteins<span class="Italics"> in vitro</span>. Oxycodone has been found in breast milk (see<a href="#pre"> PRECAUTIONS</a>).</p>
<p>Aspirin is hydrolyzed primarily to salicylic acid in the gut wall and during first-pass metabolism through the liver. Salicylic acid is absorbed rapidly from the stomach, but most of the absorption occurs in the proximal small intestine. Following absorption, salicylate is distributed to most body tissues and fluids, including fetal tissues, breast milk, and the CNS. High concentrations are found in the liver and kidneys. Salicylate is variably bound to serum proteins, particularly albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Oxycodone is extensively metabolized by multiple metabolic pathways to produce noroxycodone, oxymorphone and noroxymorphone, which are subsequently glucuronidated. Noroxycodone and noroxymorphone are the major circulating metabolites. CYP3A mediated N-demethylation to noroxycodone is the primary metabolic pathway of oxycodone with a lower contribution from CYP2D6 mediated O-demethylation to oxymorphone. Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs (see<a href="#drugdrug"> Drug-Drug Interactions</a>).</p>
<p>Noroxycodone exhibits very weak anti-nociceptive potency compared to oxycodone, however, it undergoes further oxidation to produce noroxymorphone, which is active at opioid receptors. Although noroxymorphone is an active metabolite and present at relatively high concentrations in circulation, it does not appear to cross the blood-brain barrier to a significant extent. Oxymorphone, is present in the plasma only at low concentrations and undergoes further metabolism to form its glucuronide and noroxymorphone. Oxymorphone has been shown to be active and possessing analgesic activity but its contribution to <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> following oxycodone administration is thought to be clinically insignificant, based on the amount formed. Other metabolites (α- and β-oxycodol, noroxycodol and oxymorphol) may be present at very low concentrations and demonstrate limited penetration into the brain as compared to oxycodone. The enzymes responsible for keto-reduction and glucuronidation pathways in oxycodone metabolism have not been established.</p>
<p>The biotransformation of aspirin occurs primarily in the liver by the microsomal enzyme system. With a plasma half-life of approximately 15 minutes, aspirin is rapidly hydrolyzed to salicylate. At low doses, salicylate elimination follows first-order kinetics. The plasma half-life of salicylate is approximately 2 to 3 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.5.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Free and conjugated noroxycodone, free and conjugated oxycodone, and oxymorphone are excreted in human urine following a single oral dose of oxycodone. Approximately 8% to 14% of the dose is excreted as free oxycodone over 24 hours after administration.</p>
<p>Approximately 10% of aspirin is excreted as unchanged salicylate in the urine. The major metabolites excreted in the urine are salicyluric acid (75%), salicyl phenolic glucuronide (10%), salicyl acyl glucuronide (5%), and gentisic and gentisuric acid (less than 1%) each. Eighty to 100% of a single dose is excreted in the urine within 24 to 72 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="drugdrug"></a><a name="section-3.6"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First"><span class="Bold">(see<a href="#pre"> PRECAUTIONS</a>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.1"></a><p></p>
<h3>Inhibitors of CYP3A4</h3>
<p class="First">Since the CYP3A4 isoenzyme plays a major role in the metabolism of oxycodone and aspirin, drugs that inhibit CYP3A4 activity, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations. A published study showed that the co-administration of the antifungal drug, voriconazole, increased oxycodone AUC and C<span class="Sub">max</span> by 3.6 and 1.7 fold, respectively. The expected clinical results would be increased or prolonged opioid effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.6.2"></a><p></p>
<h3>Inducers of CYP450</h3>
<p class="First">CYP450 inducers, such as rifampin, carbamazepine, and phenytoin, may induce the metabolism of oxycodone, may cause increased clearance of the drug which could lead to a decrease in oxycodone plasma concentrations. A published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, decreased oxycodone (oral) AUC and C<span class="Sub">max</span> by 86% and 63% respectively. The expected clinical results would be lack of efficacy or, possibly, development of abstinence syndrome in a patient who had developed physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> to oxycodone. Induction of CYP3A4 may be of greatest importance given oxycodone's metabolic pathways.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Oxycodone and aspirin tablets are indicated for the management of moderate to moderately severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Oxycodone and aspirin tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to oxycodone or aspirin, and in any situation where opioids or aspirin are contraindicated. Aspirin is contraindicated for patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Reye Syndrome</h2>
<p class="First"><span class="Bold">Aspirin should not be used in children or teenagers for <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>, with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, because of the risk of Reye syndrome with concomitant use of aspirin in certain viral illnesses. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></h2>
<p class="First">Aspirin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to nonsteroidal anti-inflammatory drug products and in patients with the syndrome of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, and <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>. Aspirin may cause severe <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> (<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>).</p>
<p>Oxycodone is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to oxycodone. Oxycodone is contraindicated in any situation where opioids are contraindicated including patients with significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>. Oxycodone is contraindicated in the setting of suspected or known <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Misuse and Abuse of Opioids</h2>
<p class="First">Oxycodone is an opioid agonist of the morphine-type. Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion (see<a href="#dbad"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a>).</p>
<p>Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing oxycodone and aspirin tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Concerns about misuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Oxycodone and aspirin tablets may be abused by crushing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Healthcare professionals should contact their State Professional Licensing Board, or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product. </p>
<p>Administration of oxycodone and aspirin tablets should be closely monitored for the following potentially serious adverse reactions and complications:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is a hazard with the use of oxycodone, one of the active ingredients in oxycodone and aspirin tablets, as with all opioid agonists. Elderly and debilitated patients are at particular risk for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> as are non-tolerant patients given large initial doses of oxycodone or when oxycodone is given in conjunction with other agents that depress respiration. Oxycodone should be used with extreme caution in patients with acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, chronic obstructive <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">pulmonary disorder</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, or preexisting respiratory impairment. In such patients, even usual therapeutic doses of oxycodone may decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. In these patients alternative non-opioid analgesics should be considered, and opioids should be employed only under careful medical supervision at the lowest effective dose.</p>
<p>In case of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, a reversal agent such as naloxone hydrochloride may be utilized (see<a href="#overdosage"> OVERDOSAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h3>
<p class="First">The respiratory depressant effects of opioids include <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention and secondary elevation of cerebrospinal fluid pressure, and may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions or a pre-existing increase in intracranial pressure. Oxycodone produces effects on pupillary response and consciousness which may obscure neurologic signs of worsening in patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3>Hypotensive Effect</h3>
<p class="First">Oxycodone may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> particularly in individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs which compromise vasomotor tone such as phenothiazines. Oxycodone, like all opioid analgesics of the morphine-type, should be administered with caution to patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, since vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure. Oxycodone may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<h3>Alcohol Warning</h3>
<p class="First">Patients who consume three or more alcoholic drinks every day should be counseled about the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risks involved with chronic, heavy alcohol use while taking aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<h3>Coagulation Abnormalities</h3>
<p class="First">Even low doses of aspirin can inhibit platelet function leading to an increase in <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. This can adversely affect patients with inherited (<span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>) or acquired (liver disease or <span class="product-label-link" type="condition" conceptid="435781" conceptname="Vitamin K deficiency">vitamin K deficiency</span>) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6"></a><p></p>
<h3>GI Side Effects</h3>
<p class="First">GI side effects include <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and gross GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Although minor upper GI symptoms, such as <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, are common and can occur anytime during therapy, physicians should remain alert for signs of ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, even in the absence of previous GI symptoms. Physicians should inform patients about the signs and symptoms of GI side effects and what steps to take if they occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcer Disease</span></h3>
<p class="First">Patients with a history of active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> should avoid using aspirin, which can cause gastric mucosal irritation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="pre"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Opioid analgesics should be used with caution when combined with CNS depressant drugs, and should be reserved for cases where the benefits of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> outweigh the known risks of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, altered mental state, and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p>Oxycodone and aspirin tablets should be given with caution to patients with <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, elderly or debilitated patients, patients with severe impairment of hepatic, pulmonary, or renal function, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>, kyphoscoliosis with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span>, and toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p>Oxycodone and aspirin tablets may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Oxycodone may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and all opioids may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings.</p>
<p>Following administration of oxycodone and aspirin tablets, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have been reported in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to codeine, a compound with a structure similar to morphine and oxycodone. The frequency of this possible cross-sensitivity is unknown.</p>
<p>Aspirin has been associated with elevated hepatic enzymes, blood urea nitrogen and serum creatinine, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, and prolonged <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First">Aspirin may increase the likelihood of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> due to its effect on the gastric mucosa and platelet function (prolongation of <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>). Salicylates should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> or coagulation abnormalities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Interactions with Other CNS Depressants</h2>
<p class="First">Patients receiving other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, centrally-acting anti-emetics, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone and aspirin tablets may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When such combined therapy is contemplated, the dose of one or both agents should be reduced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Interactions with Mixed Agonist/Antagonist Opioid Analgesics</h2>
<p class="First">Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone. In this situation, mixed agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of oxycodone and/or may precipitate withdrawal symptoms in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Ambulatory Surgery and Postoperative Use</h2>
<p class="First">Oxycodone and other morphine- like opioids have been shown to decrease bowel motility. <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span> is a common postoperative complication, especially after intra-abdominal surgery with use of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Caution should be taken to monitor for decreased bowel motility in postoperative patients receiving opioids. Standard supportive therapy should be implemented.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></h2>
<p class="First">Oxycodone may cause spasm of the sphincter of Oddi and should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. Opioids like oxycodone may cause increases in the serum amylase level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2>Tolerance and Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is the need for increasing doses of opioids to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are not unusual during chronic opioid therapy.</p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including: <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> or heart rate. </p>
<p>In general, opioids should not be abruptly discontinued (see<a href="#cot"> DOSAGE AND ADMINISTRATION: Cessation of Therapy</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.8"></a><p></p>
<h2>Information for Patients/Caregivers</h2>
<p class="First"><span class="Bold Italics">The following information should be provided to patients receiving oxycodone and aspirin tablets by their physician, nurse, pharmacist, or caregiver:</span></p>
<ol class="Arabic">
<li>Patients should be aware that oxycodone and aspirin tablets contain oxycodone, which is a morphine-like substance.</li>
<li>Patients should be instructed to keep oxycodone and aspirin tablets in a secure place out of the reach of children. In the case of accidental ingestions, emergency medical care should be sought immediately.</li>
<li>When oxycodone and aspirin tablets are no longer needed, the unused tablets should be destroyed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> down the toilet.</li>
<li>Patients should be advised not to adjust the medication dose themselves. Instead, they must consult with their prescribing physician.</li>
<li>Patients should be advised that oxycodone and aspirin tablets may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).</li>
<li>Patients should not combine oxycodone and aspirin tablets with alcohol, opioid analgesics, tranquilizers, sedatives, or other CNS depressants unless under the recommendation and guidance of a physician. When co-administered with another CNS depressant, oxycodone and aspirin tablets can cause dangerous additive central nervous system or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, which can result in serious injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>The safe use of oxycodone and aspirin tablets during pregnancy has not been established; thus, women who are planning to become pregnant or are pregnant should consult with their physician before taking oxycodone and aspirin tablets. </li>
<li>Nursing mothers should consult with their physicians about whether to discontinue nursing or discontinue oxycodone and aspirin tablets because of the potential for serious adverse reactions to nursing infants.</li>
<li>Patients who are treated with oxycodone and aspirin tablets for more than a few weeks should be advised not to abruptly discontinue the medication. Patients should consult with their physician for a gradual discontinuation dose schedule to taper off the medication.</li>
<li>Patients should be advised that oxycodone and aspirin tablets are a potential drug of abuse. They should protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and it should never be given to anyone other than the individual for whom it was prescribed.</li>
<li>Patients should be advised that oxycodone and aspirin tablets may cause or worsen <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, as generally occurs with all opioids. They should discuss any past history of <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> with their prescribing physician so a management plan may be initiated. </li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.9"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Although oxycodone may cross-react with some drug urine tests, no available studies were found which determined the duration of detectability of oxycodone in <span class="product-label-link" type="condition" conceptid="4215138" conceptname="Drug screening test">urine drug screens</span>. However, based on pharmacokinetic data, the approximate duration of detectability for a single dose of oxycodone is roughly estimated to be one to two days following drug exposure.</p>
<p>Urine testing for opiates may be performed to determine illicit drug use and for medical reasons such as evaluation of patients with altered states of consciousness or monitoring efficacy of drug rehabilitation efforts. The preliminary identification of opiates in urine involves the use of an immunoassay screening and thin-layer chromatography (TLC). Gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometry (GC/MS) may be utilized as a third-stage identification step in the medical investigational sequence for opiate testing after immunoassay and TLC. The identities of 6-keto opiates (e.g., oxycodone) can further be differentiated by the analysis of their methoxime-trimethylsilyl (MO-TMS) derivative.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.10"></a><p></p>
<h2>Drug/Drug Interactions with Oxycodone</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10.1"></a><p></p>
<h3>CYP3A4 Inhibitors and CYP450 Inducers</h3>
<p class="First">Oxycodone is extensively metabolized by multiple metabolic pathways. CYP3A4 is the major enzyme involved in noroxycodone formation followed by CYP2B6, CYP2C9/19 and CYP2D6. Drugs that inhibit CYP3A4 activity, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations and prolonged opioid effects. Similarly, CYP450 inducers, such as rifampin, carbamazepine, and phenytoin, may induce the metabolism of oxycodone and, therefore, may cause increased clearance of the drug which could lead to a decrease in oxycodone plasma concentrations, lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> to oxycodone.</p>
<p>If co-administration with oxycodone and aspirin tablets is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors or CYP450 inducers. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10.2"></a><p></p>
<h3>Skeletal Muscle Relaxants</h3>
<p class="First">Opioid analgesics may enhance the neuromuscular-blocking action of skeletal muscle relaxants and produce an increase in the degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10.3"></a><p></p>
<h3>CNS Depressants</h3>
<p class="First">Patients receiving CNS depressants such as other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, centrally-acting anti-emetics, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone and aspirin tablets may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When such combined therapy is contemplated, the dose of one or both agents should be reduced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10.4"></a><p></p>
<h3>Analgesics</h3>
<p class="First">Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, naltrexone, and butorphanol) should be administered with caution to a patient who has received or is receiving a pure opioid agonist such as oxycodone. These agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of oxycodone or may precipitate withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.11"></a><p></p>
<h2>Drug/Drug Interactions with Aspirin</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.1"></a><p></p>
<h3>Angiotensin Converting Enzyme (ACE) Inhibitors</h3>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremic</span> and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of aspirin due to its indirect effect on the renin-angiotensin conversion pathway.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.2"></a><p></p>
<h3>Acetazolamide</h3>
<p class="First">Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.3"></a><p></p>
<h3>Anticoagulant Therapy (Heparin and Warfarin)</h3>
<p class="First">Patients on anticoagulation therapy are at increased risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> because of drug-drug interactions and the effect on platelets. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and the <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>. Aspirin can increase the anticoagulant activity of heparin, increasing <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.4"></a><p></p>
<h3>Anticonvulsants</h3>
<p class="First">Salicylate can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.5"></a><p></p>
<h3>Beta Blockers</h3>
<p class="First">The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.6"></a><p></p>
<h3>Diuretics</h3>
<p class="First">The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.7"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">Aspirin may enhance the serious side and toxicity of methotrexate due to displacement from its plasma protein binding sites and/or reduced renal clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.8"></a><p></p>
<h3>Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</h3>
<p class="First">The concurrent use of aspirin with other NSAIDs should be avoided because this may increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or lead to decreased renal function. Aspirin may enhance the serious side effects and toxicity of ketorolac, due to displacement from its plasma protein binding sites and/or reduced renal clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.9"></a><p></p>
<h3>Oral Hypoglycemics Agents</h3>
<p class="First">Aspirin may increase the serum glucose- lowering action of insulin and sulfonylureas leading to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11.10"></a><p></p>
<h3>Uricosuric Agents</h3>
<p class="First">Salicylates antagonize the uricosuric action of probenecid or sulfinpyrazone.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.12"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Depending on the sensitivity/specificity and the test methodology, the individual components of oxycodone and aspirin tablets may cross-react with assays used in the preliminary detection of cocaine (primary urinary metabolite, benzoylecgonine) or marijuana (cannabinoids) in human urine. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. The preferred confirmatory method is gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometry (GC/MS). Moreover, clinical considerations and professional judgment should be applied to any drug-of -abuse test result, particularly when preliminary positive results are used.</p>
<p>Salicylates may increase the protein bound iodine (PBI) result by competing for the protein binding sites on pre-albumin and possibly thyroid-binding globulins.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.13"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.13.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Animal studies to evaluate the carcinogenic potential of oxycodone and aspirin have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.13.2"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First">The combination of oxycodone and aspirin has not been evaluated for mutagenicity. Oxycodone alone was negative in a bacterial reverse mutation assay (Ames),<span class="Italics"> an in vitro </span>chromosome aberration assay with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> without metabolic activation and an<span class="Italics"> in vivo </span>mouse micronucleus assay. Oxycodone was clastogenic in the human lymphocyte chromosomal assay in the presence of metabolic activation and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay with or without metabolic activation. Aspirin induced chromosome aberrations in cultured human fibroblasts.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.13.3"></a><p></p>
<h3>Fertility</h3>
<p class="First">Animal studies to evaluate the effects of oxycodone on fertility have not been performed. Aspirin has been shown to inhibit ovulation in rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.14"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.14.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14.1.1"></a><p></p>
<h4>Oxycodone</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14.1.1.1"></a><p></p>
<h5>Pregnancy Category B</h5>
<p class="First">Reproduction studies in rats and rabbits demonstrated that oral administration of oxycodone was not teratogenic or embryo-fetal toxic.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14.1.2"></a><p></p>
<h4>Aspirin</h4>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.14.1.2.1"></a><p></p>
<h5>Pregnancy Category D </h5>
<p class="First"><span class="Italics">(see<a href="#pre"> PRECAUTIONS</a>)</span></p>
<p>Salicylates readily cross the placenta and by inhibiting prostaglandin synthesis, may cause constriction of ductus arteriosus resulting in <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> and increased fetal mortality and, possibly other untoward fetal effects. Aspirin use in pregnancy can also result in alteration in maternal and neonatal hemostasis mechanisms. Maternal aspirin use during later stages of pregnancy may cause low birth weight, increased incidence of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> in premature infants, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Use during pregnancy, especially in the third trimester, should be avoided.</p>
<p>Safe use of oxycodone and aspirin tablets in pregnancy has not been established relative to possible adverse effects on fetal development. Therefore, oxycodone and aspirin tablets should not be used in pregnant women unless, in the judgment of the physician, the potential benefits outweigh the possible hazards.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.15"></a><p></p>
<h2>Nonteratogenic Effects</h2>
<p class="First">Opioids can cross the placental barrier and have the potential to cause <span class="product-label-link" type="condition" conceptid="4318857" conceptname="Neonatal respiratory depression">neonatal respiratory depression</span>. Opioid use during pregnancy may result in a physically drug-dependent fetus. After birth, the neonate may suffer severe withdrawal symptoms. Aspirin may produce <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, anteor <span class="product-label-link" type="condition" conceptid="443929" conceptname="Postpartum hemorrhage">postpartum hemorrhage</span>, prolonged gestation and labor, and <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span>.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.16"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Oxycodone and aspirin tablets are not recommended for use in women during and immediately prior to labor and delivery due to its potential effects on respiratory function in the newborn. Aspirin should be avoided one week prior to and during labor and delivery because it can result in excessive blood loss at delivery. Prolonged gestation and <span class="product-label-link" type="condition" conceptid="434714" conceptname="Prolonged second stage of labor">prolonged labor</span> due to prostaglandin inhibition have been reported.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.17"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Ordinarily, nursing should not be undertaken while a patient is receiving oxycodone and aspirin tablets because of the possibility of sedation and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the infant. Oxycodone is excreted in breast milk in low concentrations, and there have been rare reports of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> in babies of nursing mothers taking an oxycodone/acetaminophen product. Salicylic acid has also been detected in breast milk. Adverse effects on platelet function in the nursing infant exposed to aspirin in breast milk may be a potential risk. Furthermore, the risk of<span class="Bold"> Reye Syndrome </span>caused by salicylate in breast milk is unknown. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential benefits to the woman and the possible hazards to the nursing infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.18"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Oxycodone and aspirin tablets should not be administered to pediatric patients. Reye Syndrome is a rare but serious disease which can follow flu or chicken pox in children and teenagers. While the cause of Reye Syndrome is unknown, some reports claim aspirin (or salicylates) may increase the risk of developing this disease.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.19"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Special precaution should be given when determining the dosing amount and frequency of oxycodone and aspirin tablets for geriatric patients, since clearance of oxycodone may be slightly reduced in this patient population when compared to younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.20"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In a pharmacokinetic study of oxycodone in patients with end-stage liver disease, oxycodone plasma clearance decreased and the elimination half- life increased. Care should be exercised when oxycodone is used in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>Avoid aspirin in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.21"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In a study of patients with end stage <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, mean elimination half- life of oxycodone was prolonged in uremic patients due to increased volume of distribution and reduced clearance. Oxycodone should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Avoid aspirin in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (glomerular filtration rate less than 10 mL/minute).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions that may be associated with oxycodone and aspirin tablet use include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (see<a href="#overdosage"> OVERDOSAGE</a>).</p>
<p>The most frequently observed non-serious adverse reactions include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>Aspirin may increase the likelihood of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> due to its effect on the gastric mucosa and platelet function. Furthermore, aspirin has the potential to cause <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> in hypersensitive patients as well as <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> especially in patients with <span class="product-label-link" type="condition" conceptid="4198855" conceptname="Chronic urticaria">chronic urticaria</span>. Other adverse reactions due to aspirin use include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, reversible hepatotoxicity, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, decreased plasma iron concentration, and shortened erythrocyte survival time.</p>
<p>Other adverse reactions obtained from post-marketing experiences with oxycodone and aspirin tablets are listed by organ system and in decreasing order of severity and/or frequency as follows:</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, non-accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> </p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="Bold">Central and Peripheral Nervous System: </span><span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, subdural or <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">mental impairment</span></p>
<p><span class="Bold">Fluid and Electrolyte: </span><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span></p>
<p><span class="Bold">Gastrointestinal: </span>hemorrhagic gastric/<span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, gastric/<span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, transient elevations of hepatic enzymes, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, Reye syndrome, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span></p>
<p><span class="Bold">Hearing and Vestibular: </span><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. Patients with high frequency loss may have difficulty perceiving <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. In these patients, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> cannot be used as a clinical indicator of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span>.</p>
<p><span class="Bold">Hematologic: </span>unspecified <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4261785" conceptname="Reticulocytosis">reticulocytosis</span>, prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> </p>
<p><span class="Bold">Metabolic and Nutritional: </span><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span></p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span></p>
<p><span class="Bold">Ocular: </span><span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eye</span></p>
<p><span class="Bold">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span>, drug abuse, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span></p>
<p><span class="Bold">Reproductive: </span><span class="product-label-link" type="condition" conceptid="432695" conceptname="Post-term pregnancy">prolonged pregnancy</span> and labor, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>, lower birth weight infants, antepartum and postpartum <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, closure of patent ductus arteriosis</p>
<p><span class="Bold">Respiratory System: </span><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperpnea</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span></p>
<p><span class="Bold">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<p><span class="Bold">Urogenital: </span>interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and failure, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="overdosage"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with oxycodone and aspirin tablets is characterized by signs and symptoms of opioid and salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Oxycodone overdosage can be manifested by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, pupillary constriction (pupils may be dilated in the setting of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>), and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. Early signs of acute aspirin (salicylate) <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> including <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> occur at plasma concentrations approaching 200 mcg/mL. Plasma concentrations of aspirin above 300 mcg/mL are toxic. Severe toxic effects are associated with levels above 400 mcg/mL. A single lethal dose of aspirin in adults is not known with certainty but <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may be expected at 30 g. For real or suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a Poison Control Center should be contacted immediately.</p>
<p>In acute salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, severe acid-base and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> may occur and are complicated by <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">Respiratory alkalosis</span> occurs early while <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> is present, but is quickly followed by <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. Serious symptoms such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> progress rapidly. </p>
<p><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Salicylism</span> (chronic salicylate toxicity) may be noted by symptoms such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, difficulty hearing, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>. More severe <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span> may result in <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. Supportive measures (including oxygen, intravenous fluids, and vasopressors) should be employed in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation. Treatment of acid-base disturbances and electrolyte disorders is also important. Because of the concern over salicylate toxicity, acid-base status should be followed closely with serial blood gas and serum pH determinations.</p>
<p>The opioid antagonist naloxone hydrochloride is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to opioids including oxycodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered (usual initial adult dose 0.4 mg-2 mg) preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Since the duration of action of oxycodone may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> secondary to oxycodone <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In patients who are physically dependent on any opioid agonist including oxycodone, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome. The severity of the withdrawal syndrome produced will depend on the degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and the dose of the antagonist administered. Please see the prescribing information for the specific opioid antagonist for details of their proper use.</p>
<p>Gastric emptying and/or lavage may be useful in removing unabsorbed drug. This procedure is recommended as soon as possible after ingestion, even if the patient has <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span> spontaneously. After lavage and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, administration of activated charcoal, as a slurry, is beneficial, if less than three hours have passed since ingestion. Charcoal adsorption should not be employed prior to lavage and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</p>
<p>In severe cases of salicylate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> are the major immediate threats to life. Children should be sponged with tepid water. Replacement fluid should be administered intravenously and augmented with correction of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. Plasma electrolytes and pH should be monitored to promote alkaline <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> of salicylate if renal function is normal. Infusion of glucose may be required to control <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. With more severe acute toxicity <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span> may occur.</p>
<p>Hemodialysis and peritoneal dialysis can be performed to reduce the body content of aspirin. In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or in cases of life-threatening salicylate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> dialysis is usually required. Exchange transfusion may be indicated in infants and young children.</p>
<p>In case of real or suspected <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a poison control center should be consulted for the treatment of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">salicylism</span>.</p>
<p>The toxicity of oxycodone and aspirin in combination is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be adjusted according to the severity of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and the response of the patient. It may occasionally be necessary to exceed the usual dosage recommended below in cases of more severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or in those patients who have become tolerant to the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of opioids. If <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is constant, the opioid analgesic should be given at regular intervals on an around-the-clock schedule. Oxycodone and aspirin tablets are given orally.</p>
<p>The usual dosage is one tablet every 6 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The maximum daily dose of aspirin should not exceed 4 grams or 12 tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="cot"></a><a name="section-10.1"></a><p></p>
<h2>Cessation of Therapy</h2>
<p class="First">In patients treated with oxycodone and aspirin tablets for more than a few weeks who no longer require therapy, doses should be tapered gradually to prevent signs and symptoms of withdrawal in the physically dependent patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="dbad"></a><a name="section-11"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Oxycodone and aspirin tablets are a Schedule II controlled substance. Oxycodone is a mu-agonist opioid with an abuse liability similar to morphine. Oxycodone, like morphine and other opioids used in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, can be abused and is subject to criminal diversion.</p>
<p><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is defined as an abnormal, compulsive use, use for non- medical purposes of a substance despite physical, psychological, occupational or interpersonal difficulties resulting from such use, and continued use despite harm or risk of harm. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common. Opioid addiction is relatively rare in patients with <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> but may be more common in individuals who have a past history of alcohol or <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Pseudoaddiction refers to <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief seeking behavior of patients whose <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is poorly managed. It is considered an iatrogenic effect of ineffective <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management. The health care provider must assess continuously the psychological and clinical condition of a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> patient in order to distinguish addiction from pseudoaddiction and thus, be able to treat the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> adequately.</p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on a prescribed medication does not signify addiction. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> involves the occurrence of a withdrawal syndrome when there is sudden reduction or cessation in drug use or if an opiate antagonist is administered. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> can be detected after a few days of opioid therapy. However, clinically significant physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is only seen after several weeks of relatively high dosage therapy. In this case, abrupt discontinuation of the opioid may result in a withdrawal syndrome. If the discontinuation of opioids is therapeutically indicated, gradual tapering of the drug over a 2-week period will prevent withdrawal symptoms. The severity of the withdrawal syndrome depends primarily on the daily dosage of the opioid, the duration of therapy and medical status of the individual. </p>
<p>The withdrawal syndrome of oxycodone is similar to that of morphine. This syndrome is characterized by <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, increased heart rate and blood pressure, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> alternating with <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, severe <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and pronounced <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>"Drug-seeking" behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated "loss" of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). "Doctor shopping" to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Oxycodone, like other opioids, has been diverted for non- medical use. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p>Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
<p>Like other opioid medications, oxycodone and aspirin tablets are subject to the Federal Controlled Substances Act. After chronic use, oxycodone and aspirin tablets should not be discontinued abruptly when it is thought that the patient has become physically dependent on oxycodone.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Interactions with Alcohol and Drugs of Abuse</h2>
<p class="First">Oxycodone may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Oxycodone and Aspirin Tablets, USP are supplied as a white, round, standard convex, scored tablet debossed with<span class="Bold"> 117 </span>above the score on one side of the tablet and blank on the other side. They are available as follows:</p>
<p>NDC 0378-6117-01<br>bottles of 100</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20° to 25°C (68° to 77°F). [see USP Controlled Room Temperature].</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">DEA ORDER FORM REQUIRED.</span></p>
<p>Distributed by:</p>
<p><span class="Bold">MYLAN</span><span class="Sup">®</span><br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505</p>
<p>60513</p>
<p>SEPTEMBER 2010</p>
<p>CL:OXASP:R1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 4.8355 mg/325 mg Bottle Label</h1>
<p class="First"><span class="Bold">NDC </span>0378-6117-01</p>
<p><span class="Bold">MYLAN</span><span class="Sup">®</span></p>
<p><span class="Bold">CII</span></p>
<p><span class="Bold">OXYCODONE and<br>ASPIRIN</span></p>
<p><span class="Bold">TABLETS, USP</span></p>
<p><span class="Bold">4.8355 mg*/325 mg</span></p>
<p>100 TABLETS</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 4.8355 mg/325 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b82495ce-8d77-4e12-a064-274a88448ba3&amp;name=oxycodone-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXYCODONE HYDROCHLORIDE AND ASPIRIN 		
					</strong><br><span class="contentTableReg">oxycodone hydrochloride and aspirin tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-6117</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Oxycodone Hydrochloride</strong> (Oxycodone) </td>
<td class="formItem">Oxycodone Hydrochloride</td>
<td class="formItem">4.8355 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Aspirin</strong> (Aspirin) </td>
<td class="formItem">Aspirin</td>
<td class="formItem">325 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Cellulose, Microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Silicon Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Stearic Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Starch, Corn</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">117</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-6117-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091670</td>
<td class="formItem">05/02/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Metrics, Inc.</td>
<td class="formItem"></td>
<td class="formItem">867220261</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>671f8f36-88e3-44e8-a597-376fe74bb831</div>
<div>Set id: b82495ce-8d77-4e12-a064-274a88448ba3</div>
<div>Version: 3</div>
<div>Effective Time: 20110321</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
